Global Archives – Page 15 of 25 – Treatment Action Group

Open Letter: Urgent Action Necessary to Improve Equitable Access to GeneXpert TB Diagnostics and Achieve 1/4/6×24

February 2, 2021
Dorrit Walsh

A coalition of civil society activists, including TAG, public health leaders, and researchers sent this letter with information about the 1/4/6x24 Campaign...

Harnessing the COVID-19 Response Towards Hepatitis C Elimination

February 1, 2021
Dorrit Walsh

On Wednesday, February 3, 2021, Treatment Action Group, Médecins du Monde, hepCoalition, and the UNITE network convene a virtual policy dialogue among parliamentarians, global civil society organizations, and community leaders to share how COVID-19 has impacted global hepatitis C virus (HCV) elimination efforts.

Cover of the brief: Hepatitis C and COVID-19 Global Concerns: Sustained Financing and Expanded Access to Testing and Pangenotypic Treatments Needed to Recover the Path to Elimination

Hepatitis C and COVID-19 Global Concerns: Sustained Financing and Expanded Access to Testing and Pangenotypic Treatments Needed to Recover the Path to Elimination

February 1, 2021
Dorrit Walsh

This policy brief highlights strategies that leverage the COVID-19 response towards improving access to HCV diagnostics, treatment, and care.

TAG/COVID-19 Prevention Network: HIV, COVID-19 Outcomes and Implications for COVID-19 Vaccines

January 26, 2021
Dorrit Walsh

Join TAG and COVID-19 Prevention Network (CoVPN) On Tuesday February 2nd at 4pm ET / 1pm PT, at a webinar for community advocates on COVID-19 outcomes in people living with HIV and implications for COVID-19 vaccines.

TAG and COVID-19 Prevention Network Fall 2020 Webinars

December 16, 2020
Dorrit Walsh

TAG is hosting a series of webinars on COVID-19 biomedical prevention research in collaboration with the CoVPN. Information and videos from the first two events may be found on this page.

US FDA COVID Vaccine Authorization Important Step Toward Ending the COVID-19 Pandemic

December 11, 2020
Dorrit Walsh

Today’s decision by the US Food and Drug Administration (FDA) to grant an Emergency Use Authorization (EUA) for the Pfizer-BioNTech mRNA vaccine is an important step toward bringing the COVID-19 pandemic under control in the United States.

Cover of Tuberculosis Research Funding Trends 2005-2019

2020 Report on TB Research Funding Trends

December 7, 2020
Dorrit Walsh

TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2019 and analyzes trends in funding since 2005.

Investment in HIV Research Profoundly Benefits the COVID-19 Response

December 2, 2020
Dorrit Walsh

This policy brief discusses how investment in HIV research has profoundly benefitted the COVID-19 response, and advocates that continued financial support for HIV science can both ensure progress on COVID-19 and avoid losing ground—and lives—in the fight to end the HIV epidemic.

COVID-19 and Impacted Communities: A Media Communications Guide

November 12, 2020
Dorrit Walsh

This easy-to-use guide is designed to provide journalists and communication professionals the tools needed to ensure accurate reporting and curb any related stigma associated with the novel coronavirus SARS-COV-2, also known and reported as COVID-19. We invite you to use this to inform your own writing and to share it with colleagues and cohorts that work in media and communications.

Treatment Action Group Statement on Early Findings from HPTN 084

November 12, 2020
Dorrit Walsh

Treatment Action Group welcomes the announcement that the phase 3 HPTN 084 trial proved that intramuscular injections of ViiV’s long acting cabotegravir (CAB-LA) every eight weeks were superior to daily oral TDF/FTC pre-exposure prophylaxis (PrEP) in preventing new HIV infections in cisgender women in sub-Saharan Africa.